Recombinant growth hormone therapy in a girl with costello syndrome: a 4-year observation

Ewa Blachowska1*, Elżbieta Petriczko1, Anita Horodnicka-Józwa1, Agata Skórka2,3, Magdalena Pelc2, Małgorzata Krajewska-Walasek2 and Mieczysław Walczak1

Abstract

Background: Costello syndrome is a rare syndrome of multiple congenital anomalies. The typical clinical traits include dysmorphic craniofacial features, skin hyperpigmentation and excess, feeding difficulties leading to severe postnatal growth retardation, short stature, joint hypermobility, and delayed psychomotor development. Additionally, Costello syndrome may present with an increased incidence of congenital heart disease, hypertrophic cardiomyopathy, and increased risk of both benign and malignant tumors. Furthermore, cases of patients with endocrine disorders such as adrenal insufficiency and endogenous growth hormone deficiency have also been documented.

Case presentation: We present a patient with Costello syndrome who has been successfully treated with recombinant human growth hormone (rhGH) for almost 4 years.

Conclusions: The possibility of growth hormone (GH) treatment can be considered in cases of documented GH deficiency in patients with Costello syndrome, but only under close oncologic and cardiologic supervision.

Keywords: Costello syndrome, Growth hormone deficiency, Hypertrophic cardiomyopathy, Malignancy, HRAS gene

Background

Costello syndrome (CS, OMIM #218040) is caused by heterozygous germline mutations in the proto-oncogene HRAS that cause dysfunction of the Ras-MAPK signaling pathway. To date, 15 mutations in HRAS have been identified. The birth prevalence of this disease is estimated at 1:1,230,000 to 1:300,000 [1–4]. Clinically, CS is characterized by polyhydramnios, high birth weight, postnatal growth retardation, relative macrocephaly, coarse facial features, loose skin, especially of the hands and feet, hyperpigmentation, hypertrophic cardiomyopathy, atrial arrhythmias, papillomas, developmental delay or mental retardation, and predisposition to malignancies. In the newborn and neonatal periods, the presence of suggestive facies and severe feeding difficulties leading to failure to thrive and hypoglycemia help make the correct diagnosis [5–7]. Furthermore, cases of Costello syndrome patients with endocrine disorders such as adrenal insufficiency and endogenous growth hormone deficiency have also been documented in the literature [8–11].

Due to the complex nature of the discussed syndrome, patients require multidisciplinary care (provided by cardiologists, speech therapists, gastroenterologists, orthopedic surgeons) along with early stimulation and developmental support. Because of the short stature and growth hormone deficiency in this condition, growth hormone therapy is often considered. For decades there has been great debate on the anticipated risk of carcinogenesis and cardiomyopathy weighted against the potential benefits resulting from recombinant human growth hormone (rhGH) therapy. To date, there are no conclusive data showing a negative role of rhGH therapy in the development of these diseases.

Here we report a six-year-old patient with Costello syndrome, who has been successfully treated with rhGH for 42 months.

Case presentation

AM, was born at 40 weeks gestation by caesarean section (due to large fetal mass) as the first baby of healthy...
and nonconsanguineous parents with a birth weight of 4270 g (>97 c), length of 55 cm (50 c) and head circumference of 38 cm (>97c). Her Apgar score was 7/7/8 points. The pregnancy was complicated by polyhydramnios and impaired glucose tolerance in the mother.

In the neonatal period, generalized edema, hypoglycemia, and hypocalcaemia were observed. Transthoracic echocardiography revealed thickened muscles of both ventricles and septum, although follow-up cardiac examinations revealed no evidence of cardiomyopathy.

During the first two years of life the child was repeatedly hospitalized due to a number of problems (the clinical symptoms observed in the patient are presented in Table 1). At the age of 8 weeks the girl was evaluated due to failure to thrive. Physical examination revealed: poorly developed subcutaneous tissue with excess skin (this was attributed to resolution of edema), reduced muscle tone, and enlarged liver. Laboratory tests did not find evidence of hypothyroidism or inborn errors of metabolism. Ultrasonography followed by gastric scintiscan and upper GI series revealed hiatal hernia and gastric endoscopy, the latter being the base for a diagnosis of gastroesophageal reflux. Additionally, the 24-h esophageal pH study was conducted, to further help with diagnosis, yielding inconsistent results that were borderline normal. At the age of four months the patient manifested psychomotor delay, joint laxity, variable muscle tone, and hyperactive knee reflexes. Follow-up cardiac examinations revealed no signs of cardiomyopathy, but complex premature ventricular and supraventricular contractions and sinus arrest were present. She required treatment with amiodarone, which was withdrawn after one month. No cardiac arrhythmias were shown in subsequent 24-h Holter monitoring.

The treatment of gastroesophageal reflux, which involved proton pump inhibitors and prokinetic agents, was ineffective. During eight months, her weight gain had been only 1000 g. At the age of nine months the patient weighed 4970 g (SD: –4.35), and underweight, 10.7 kg (SD: –2.86). Routine laboratory tests did not show any abnormalities. Electrocardiographic examination and abdominal ultrasound were normal. Hormone analysis revealed normal thyroid function, normal daily cortisol profile and rhythm. Reduced levels of insulin-like growth factor 1 in relation to chronological age were detected (26.3 ng/ml, normal level range at this age 49–289 ng/ml). Bone age was found to be consistent with the chronological age. Growth hormone levels did not reach normal values in the nocturnal secretion test or in L-Dopa and clonidine stimulation tests (maximum secretion: 8 ng/ml), see Table 2 for details. Based on the above findings and clinical observations, partial endogenous growth hormone deficiency was established.

At the age of 3 years and 9 months the girl was qualified for growth hormone therapy, following careful considerations of the risks and benefits and discussion of the issue with the child’s parents.

Growth hormone was administered by subcutaneous injection once daily, in the evening, at a dose of 0.031 mg/kg/day. Initially, the check-up visits in the Department were held every three months, and then every six months. The following issues were evaluated: response to treatment, tolerability, and laboratory test results, with particular emphasis on carbohydrate metabolism and bone age progression (Table 3).

During the initial check-ups, significant acceleration of growth was recorded. Throughout the first year of treatment, her growth rate was 9.49 cm/year, and in the next two years it was 12.36 cm/year and 7.71 cm/year, respectively, while during the pretreatment period her average growth rate was 4.28 cm/year. The curves of the patient’s body weight and height gain before and during rhGH treatment are shown in Fig. 2a and b.

During the treatment, progression of the abnormalities within the ligaments of the ankles and hip joints (right club foot, left plano-valgus foot, shortening of the Achilles tendon, dislocation of the right hip) was observed. At the age of 5 years and 6 months, surgical correction of both feet was necessary due to further progression of mobility impairment, and plasty of the hip joint was performed in the following year. At present, the patient is recovering after the last intervention.

Currently, after 42 months of rhGH treatment, the girl has grown 30.3 cm, reaching a body height above the 3rd
| Child's age | Lack of appetite | Vomiting, spitting up | Dysphagia | Esophagitis | Underweight | Hepatomegaly | Neurological abnormalities | Delayed speech development | Loose skin | Coarse facial features | Arrhythmias | Hypertrophic cardiomyopathy | Excessive joint laxity | Achilles tendon contractures | Short stature |
|-------------|------------------|----------------------|-----------|-------------|-------------|-------------|--------------------------|--------------------------|------------|------------------------|-------------|----------------------------|------------------|-------------------------|--------------|
| 1 month     | +                | +                    | +         | +           |             |             |                          | a                        | +          |                        |             |                           |                  |                         |              |
| 2–3 months  | +                | +                    | +         | +           |             |             |                          | +                        |            |                        |             |                           |                  |                         |              |
| 4–6 months  | +                | +                    | +         | +           | +           |             | +                       | +                        | +          |                        |             |                           |                  |                         |              |
| 7–9 months  | +                | +                    | +         | +           | +           |             | +                       | +                        | +          |                        |             |                           |                  |                         |              |
| 11–24 months| +                | +                    | +         | +           | +           |             |                          | +                        | +          |                        |             |                           |                  | +                       |              |
| 24–36 months| +                |                      | +         | +           | +           |             |                          | +                        | +          |                        |             |                           |                  | +                       |              |
| >3 years of life | +            |                      | +         | +           | +           |             |                          | +                        | +          |                        |             |                           |                  | +                       |              |

**Key**

*a* Edema

*b* Suspicion, later studies did not confirm hypertrophic cardiomyopathy

*c* Transient

*d* Reduced muscle tone, periodic spasticity of the lower limbs
percentile (115 cm; SD: −1.61), her weight gain has been 10.4 kg. Her current weight is 20.3 kg (10–25 percentile; SD: −1.28). So far, no serious adverse events have been observed. The patient tolerates daily injections of growth hormone well, she receives comprehensive speech therapy and rehabilitation, and attends kindergarten. Her parents have observed a significant improvement in her psychomotor development, especially with respect to speech.

Discussion
Costello syndrome was first described in 1977 by Jack Costello, a New Zealand pediatrician, in two unrelated children who presented similar phenotypic characteristics. The molecular etiology of this syndrome (germline mutations in the HRAS gene) was identified in 2005 [2]. Among many dysfunctions associated with this condition, impaired growth is one of the most challenging clinical problems [8, 12, 13]. The average final height in Costello syndrome patients, without growth-stimulating therapy, reaches about 138 cm (118–148 cm) [7]. The pathogenesis of short stature associated with this condition has been studied in recent decades. The first cases diagnosed with partial/total endogenous growth hormone deficiency and treated with rhGH were described in the 1990s [9–11]. To date, there are few studies in the scientific literature that assess the safety and efficacy of rhGH therapy in individual patients [14, 15]. As the syndrome is extremely rare, evaluating a larger group of patients seems to be a very difficult task. Increased incidence of cancer and increased risk of development of hypertrophic cardiomyopathy are serious clinical problems that should be taken into account when considering treatment with rhGH [1, 7, 8, 15]. Gripp et al. [5] estimated that the risk of developing tumors in patients with Costello syndrome reaches 17 %, most of which are rhabdomyosarcoma, neuroblastoma, papilloma, and bladder cancer. Interestingly, the p.G12A mutation detected in our patient is the main mutation associated with the higher risk of cancer in CS, which correlates with an up to 57 % risk in affected patients (2, 3). However, no occurrence of malignancy has been noted in the patient so far. Growth hormones promote cell divisions, which may generate a potential hazard. However, existing research in this area has given inconclusive results [14, 15]. Stein et al. [13] presented long-term observations involving three patients with endogenous growth hormone deficiency successfully treated with rhGH with no severe adverse events. On the other hand, cases of patients with unsatisfactory response to rhGH therapy [9] and complications during the treatment have also been documented. There are reports describing a case of a 16-year-old girl diagnosed with bladder cancer after 7 years of rhGH therapy [16], a 26-month-old boy diagnosed with rhabdomyosarcoma after one year of treatment [14], and progression of hypertrophic cardiomyopathy in a 6-year-old boy treated with rhGH [17]. However, in all of these cases it is difficult to assess whether the administration of growth hormone actually influenced the development of these diseases and to what extent.

During 3.5 years of follow-up, we have observed accelerated growth in our rhGH-treated patient, and no serious health complications have yet occurred. In infancy the girl was diagnosed with supraventricular arrhythmias and hypertrophic cardiomyopathy, which was not confirmed in subsequent echocardiography. However, because of the risk of recurrence she remains under the systematic control of a cardiologist. The observed motor-system problems, resulting from the excessive ligamentous laxity associated with Costello syndrome, were already present before the initiation of growth hormone therapy. It seems that their progression was associated with significant growth acceleration resulting
from GH supply, but the impact of rhGH therapy alone is difficult to assess.

**Conclusions**

The available data, based on a small number of reported cases of Costello syndrome treated with recombinant growth hormone, do not allow drawing general conclusions. The very good response to the treatment, demonstrated in our case, improved her body height prognosis and eliminated the disability related to extreme short stature. The 3.5-year observation revealed no serious side effects. However, reports of the other authors regarding the development and progression of cancer and hypertrophic cardiomyopathy in children

**Table 3** Selected auxological parameters of the patient during rhGH treatment

| Age [years and months] | Body height [cm] | Body height SDS | Growth rate [cm/year] | Body weight [kg] | Body weight SDS | BMI [kg/m²] | BMI SDS | Bone age [years and months] |
|------------------------|------------------|----------------|-----------------------|-----------------|----------------|-------------|---------|-----------------------------|
| 3 years 2 months       | 84               | −4.94          | 2.10                  | 10.7            | −2.86          | 15.2        | −0.504  |                             |
| 3 years 9 months       | 84.7             | −4.92          | 0.80                  | 12.1            | −2.60          | 16.9        | 1.005   | 3 years                     |
| (start of rhGH treatment) |                 |                |                       |                 |                |             |         |                             |
| 4 years                | 88.9             | −3.48          | 16.80                 | 12.1            | −2.58          | 15.3        | 0.02    |                             |
| 4 years 5 months       | 92               | −3.29          | 7.44                  | 13.3            | −2.41          | 15.7        | 0.496   |                             |
| 4 years 8 months       | 93.3             | −3.31          | 7.40                  | 14              | −2.28          | 16.1        | 0.508   | 4 years 2 months            |
| 5 years 2 months       | 97.8             | −2.84          | 5.20                  | 15.4            | −1.80          | 16.1        | 0.507   |                             |
| 5 years 6 months       | 103              | −2.02          | 9.00                  | 16              | −1.77          | 15.1        | 0.475   | 5 years – 5 years 9 months |
| 6 years 1 month        | 107.5            | −1.67          | 13.00                 | 19              | −0.92          | 16.4        | 0.511   |                             |
| 6 years 8 months       | 109              | −1.78          | 2.57$^a$              | 18.4            | −1.46          | 15.5        | 0.480   | 7 years 10 months           |
| 7 years 2 months       | 115              | −1.61          | 12.00                 | 20.3            | −1.28          | 15.3        | 0.466   |                             |

$^a$Interruptions in rhGH administration caused by orthopedic treatment

![Fig. 2 The course of growth (a) and weight gain (b) in the patient before and during rhGH treatment](image-url)
with Costello syndrome treated with rhGH indicate that these patients require special oncologic and cardiologic supervision.

**Consent**

Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

**Abbreviations**

GH: Growth hormone; HRAS: Harvey rat sarcoma viral oncogene homolog; MAPK: Mitogen-activated protein kinases; rhGH: Recombinant human growth hormone; SD: Standard deviation; GI: Gastrointestinal.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

EP and EB conceived the study, participated in its design and coordination, and helped to draft the manuscript. MKW and AS diagnosed the patient with Costello syndrome and MP carried out the molecular genetic studies, additionally, all three of them helped to draft the manuscript. MW participated in the sequence alignment. EP and EB participated in the design of the study and performed the statistical analysis. All authors read and approved the final manuscript.

**Acknowledgements**

The research was partially supported by the National Science Center Project UMO-2011/03/N/NZ2/00516 and MNiSW Project PB 0056/B/P01/2008/35. The technical and language assistance was provided by Proper Medical Writing Sp. z o.o., Warsaw, Poland.

**Author details**

1. Department of Pediatrics, Endocrinology, Diabetology, Metabolic Diseases and Cardiology of the Developmental Age, Pomeranian Medical University in Szczecin, Ulica Unii Lubelskiej 1, 71-252 Szczecin, Poland. 2. Department of Medical Genetics, The Children’s Memorial Health Institute, Warsaw, Poland. 3. Department of Pediatrics, Medical University of Warsaw, Warsaw, Poland.

Received: 4 August 2015 Accepted: 10 December 2015
Published online: 26 January 2016

**References**

1. Gripp KW, Lin AE. Costello Syndrome. GeneReviews, University of Washington, Initial Posting: August 29, 2006; Last Update: January 12, 2012.
2. Aoki Y, Nihori T, Kawame H, Kurosawa K, Ohashi H, Tanaka Y, et al. Germ-line mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet. 2005;37:1038–40.
3. Kerr B, Delrue M-A, Sigaudy S, Perveen R, Marche M, Burgelin I, et al. Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases. J Med Genet. 2006;43:401–5. doi:10.1136/jmg.2005.040352.
4. Pelc M, Ciara E, Krajewska-Walasek M. Zespół Costello jako przykład rzadkich zaburzeń funkcji szlaku sygnałowego Ras-MAPK: obraz kliniczny i diag nostyka molekularna choroby. Pediatr Pol. 2012;87:19–32.
5. Gripp KW, Scott CI, Nicholson L, McDonald-McGinn DM, Ozeran JD, Jones MC, et al. Five additional Costello syndrome patients with rhabdomyosarcoma: proposal for a tumor screening protocol. Am J Med Genet. 2002;108A:80–7.
6. Kerr B, Eden B, Dandamudi R, Shannon N, Quarrell O, Emmerson A, et al. Costello syndrome: two cases with embryonal rhabdomyosarcoma. J Med Genet. 2006;43:1036–9.
7. van Eeghen AM, van Gelderen I, Hennekam RCM. Costello syndrome: report and review. Am J Med Genet. 1999;82:187–93.
8. G Gregersen N, Vlijmoen D, Costello syndrome with growth hormone deficiency and hypoglycemia: a new report and review of the endocrine associations. Am J Med Genet Part A. 2004;129A:171–5.
9. Okamoto N, Chiyô H, Imai K, Otani K, Futagi Y. A Japanese patient with the Costello syndrome. Hum Genet. 1994;93:605–6.
10. Schimke RN, Donaldson D, Moore W. Growth hormone deficiency in Costello syndrome. Proc Greenwood Genet Ctr. 1996;15:195.
11. Yetkin I, Ayvaz G, Arslan M, Yilmaz M, Cakir N. A case of Costello syndrome with endocrine features. Ann Genet. 1998;41:157–60.
12. Legault L, Gagnon C, Lapointe N. Growth hormone deficiency in Costello syndrome: a possible explanation for the short stature. J Pediatr. 2001;138:151–2.
13. Stein RI, Legault L, Daneman D, Weksberg R, Hamilton J. Growth Hormone Deficiency in Costello Syndrome. Am J Med Genet Part A. 2004;129A:166–70.
14. Kerr B, Einandi MA, Clayton P, Gladman G, Eden T, Saunier P, et al. Is growth hormone treatment beneficial or harmful in Costello syndrome? J Med Genet. 2003;40, e74.
15. Rauen KA, Hefner E, Carrillo K, Taylor J, Messier L, Aoki Y, et al. Molecular Aspects, Clinical Aspects and Possible Treatment Modalities for Costello Syndrome: Proceedings From the 1st International Costello Syndrome Research Symposium 2007. Am J Med Genet Part A. 2008;146A:1205–17.
16. Gripp KW, Scott CI, Nicholson L, Figueroa TE. Second case of bladder carcinoma in a patient with Costello syndrome. Am J Med Genet. 2009;256–9.
17. Kobayashi D, Cook AL, Williams DA. Progressively worsening hypertrophic cardiomyopathy in a child with newly diagnosed Costello syndrome while receiving growth hormone therapy. Cardiol Young. 2010;20:459–61. doi:10.1017/S1047951110000260.EpubMar22.